Biosensors Starts Shipments of Axxion(TM) and Boosts European Distribution Network

    SINGAPORE, Aug. 30 /Xinhua-PRNewswire-FirstCall/ -- Biosensors
 International Group, Ltd. (Bloomberg: BIG SP), today announced several new
 agreements with leading medical device distributors in key European cardiology
 markets.  With a distribution reach of more than 15 countries in Europe, the
 three agreements with Krauth Medical in Germany, Invatec in Italy and Palex
 Medica in Spain will serve to strengthen Biosensors' access to key European
 markets.
     Mr Jeffrey B. Jump, Managing Director of Biosensors Europe commented: ''We
 are pleased that we have been able to attract top-tier distributors with
 proven track records of gaining significant stent market shares in Europe.
 Biosensors' agreements have the potential to generate substantial sales of
 Axxion(TM) units in Germany, Italy and Spain at attractive prices to
 Biosensors."
     Dr Stefan Widensohler, CEO of Krauth Medical, and Vice Chairman of the
 German Federal Association for Medical Technology said, ''We are excited to
 have the opportunity to commercialize Axxion(TM) in Germany, Europe's largest
 market for cardiac stents.  Krauth has been instrumental in developing the
 European market for bare metal stents over the last 25 years.  With
 Axxion(TM), we look forward to continuing our tradition of distributing
 high-quality, innovative devices in interventional cardiology."
     Axxion(TM) which elutes the Paclitaxel drug without using a polymer,
 became Biosensors' first drug-eluting stent ("DES") to be launched within
 the European Union for the treatment of coronary artery disease after it
 received Conformite Europeene (''CE'') Mark for Axxion(TM) in mid July 2005.
 Over just a month since its launch, Biosensors has already made several
 shipments of Axxion(TM) into the European market.  DES revenues have increased
 significantly as a result, compared to the same period in the first quarter of
 FY2006.
     ''This favourable response over several weeks is very encouraging and is a
 testament of the market potential for Axxion(TM),'' said Yoh-Chie Lu, Chairman
 and CEO of Biosensors.  ''We are confident that these new distributors,
 coupled with the existing network will undoubtedly allow Biosensors to capture
 a meaningful market share in the next 12 months while waiting for our second
 and highly anticipated flagship DES, the BioMatrix(TM).  BioMatrix(TM), which
 offers highly differentiated product features including bioresorbable polymer,
 will offer even stronger market appeal when it is launched.''
     Prof Eberhard Grube, who presented Biosensors' 12-month clinical trial
 results of its BioMatrix(TM) DES (known as the STEALTH trial) at Euro PCR in
 May 2005, spoke strongly of its positive clinical results and expressed
 confidence that the performance of BioMatrix(TM) is comparable, if not better
 than competing products in the market.
     The BioMatrix(TM) DES incorporates the Group's proprietary anti-restenotic
 drug, Biolimus A9TM, bioresorbable polymer, S-StentTM and stent delivery
 catheter, all of which have been developed in-house.  Biosensors believes that
 the use of a bioresorbable polymer can potentially reduce concerns about the
 long term effects of polymer coatings.  Biosensors submitted the BioMatrix(TM)
 for CE Mark regulatory approval in April this year, and expects to receive it
 by the first half of calendar 2006.
 
     About Biosensors International Group, Ltd.
     Biosensors develops, manufactures and markets innovative medical devices
 used in interventional cardiology and critical care procedures.  Biosensors is
 well-positioned to emerge as a leader in drug-eluting stents, an evolving
 therapy that is rapidly gaining market share from traditional therapies such
 as bare-metal stenting and open-heart surgery.  Biosensors has internally
 developed technology to address each component of a drug-eluting stent system,
 including a stent, a stent delivery catheter, a bioresorbable polymer and a
 proprietary anti-restenotic drug.  It is pursuing two separate drug-eluting
 stent programs, BioMatrix(TM) and Axxion(TM), and has licensed aspects of its
 drug-eluting stent technology to four companies.
 
     Forward Looking Statements
     Certain statements herein include forward-looking statements within the
 meaning of the U.S. Private Securities Litigation Reform Act of 1995.
 Forward-looking statements generally can be identified by the use of
 forward-looking terminology, such as "may," "will," "expect," "intend,"
 ''estimate,'' ''anticipate,'' ''believe,'' ''project'' or ''continue'' or the
 negative thereof or other similar words.  All forward-looking statements
 involve risks and uncertainties, including, but not limited to, customer
 acceptance and market share gains, competition from companies that have
 greater financial resources; introduction of new products into the marketplace
 by competitors; successful product development; dependence on significant
 customers; the ability to recruit and retain quality employees as Biosensors
 grows; and economic and political conditions globally.  Actual results may
 differ materially from those discussed in, or implied by, the forward-looking
 statements.  The forward-looking statements speak only as of the date of this
 release and Biosensors assumes no duty to update them to reflect new, changing
 or unanticipated events or circumstances.
 
     Media Contact Information
 
     WeR1 Consultants Pte Ltd
      Mona Leong / Stephen Chen / Reshma Jain
      Tel:   +65-6737-4844 / Hp: +65-9187-4449
      Email: monaleong@wer1.net / stephenchen@wer1.net / reshma@wer1.net
 
     Biosensors International Group
      Ms Tina Lim, Executive, Corporate Communications
      Tel:   +65-6213-5712
      Email: tina@biosensors.com.sg
      For investor related enquiries, please write to ir@biosensors.com.sg
 
 

SOURCE  Biosensors International Group, Ltd.